Shahrin Ahmed: Addressing weaknesses in invasive brain cancer by utilizing ROBO1 CAR T cells

Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X:

“Exploiting and addressing weaknesses in invasive brain cancer by utilizing ROBO1 CAR T cells –

Patients with glioblastoma (GBM), a aggressive form of brain cancer, are inevitably succumbing to recurrent disease despite the standard treatments available. The use of integrative genomic analysis shows that tumor cells take advantage of normal neurodevelopmental pathways to encourage GBM growth and invasion. A CAR T cell therapy has been developed to target this pathway and inhibit the growth of GBM and other invasive brain cancers.

The treatment of glioblastoma will be influenced by this year. A brain cancer that is both uncommon and aggressive and has a median survival time of approximately 15 to 18 months.

The results of the first pediatric patient receiving experimental CAR T-cell therapy at UPenn in 2012 were astonishing, and it was also given to adult patients in 2010. The first T cell therapy drug was approved by the FDA in 2017 five years after that. Around 34,000 patients with blood cancer have received treatment through the use of six approved drugs on the market.

The quality of human life can be greatly improved by CAR T cells, which can induce remission and even cure advanced cancer. and creating a path for a better and more sustainable world for future generations. The treatment options for glioblastoma patients are limited and haven’t seen significant innovation for decades. But a recent trial from a research group at Stanford showed that repeat infusions of CAR T cells directly into the brains of pediatric patients has benefit.”

Source: Shahrin Ahmed/X